U.S. Hemoglobinopathies Market (2024 - 2030) Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts

Market Segmentation

U.S. Hemoglobinopathies Type Outlook (Revenue in USD Million, 2018 - 2030)
- Thalassemia
- Sickle Cell Disease
- Other Hb Variants
U.S. Hemoglobinopathies Diagnosis Outlook (Revenue in USD Million, 2018 - 2030)
- Thalassemia
  - Alpha
    - Blood test
    - Genetic test
    - Prenatal test
    - Pre-implantation genetic test
    - Electrophoresis
    - Others
  - Beta
    - Blood test
    - Genetic test
    - Prenatal test
    - Pre-implantation genetic test
    - Electrophoresis
    - Others
- Sickle Cell Disease
  - Blood test
  - Genetic test
  - Prenatal test
  - Pre-implantation genetic test
  - Electrophoresis
  - Others
- Other Hb Variants
  - Blood test
  - Genetic test
  - Prenatal test
  - Pre-implantation genetic test
  - Electrophoresis
  - Others
U.S. Hemoglobinopathies Therapy Outlook (Revenue in USD Million; 2018 - 2030)
- Thalassemia
  - Alpha
    - Blood transfusion
    - Iron chelation therapy
    - Bone marrow transplant
    - Others
  - Beta
    - Blood transfusion
    - Iron chelation therapy
    - Bone marrow transplant
    - Others
- Sickle cell disease
  - Blood transfusion
  - Hydroxyurea
  - Bone marrow transplant
  - Others
- (Hb) variants
  - Blood transfusion
  - Hydroxyurea
  - Bone marrow transplant
  - Others
U.S. Hemoglobinopathies Regional Outlook (Revenue in USD Million, 2018 - 2030)
- West
- Midwest
- Northeast
- Southwest
- Southeast

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments